(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on new National Health Expenditure (NHE) data from the Centers for Medicare & Medicaid Services: “The latest National Healthcare Expenditure data from CMS offers
May is Asthma Awareness Month, and today – May 5 – is World Asthma Day. The Asthma and Allergy Foundation of America is marking the day with the release of their 2021 Asthma Capitals Report.
To help facilitate access to our nation’s nearly 70,000 retail pharmacies, PBMs are actively providing information to RxOpen, a central hub created after Hurricane Katrina to help promote uniform, consistent supply-chain information for stakeholders. PBMs also are supporting policy
(Washington, D.C) — Pharmaceutical Care Management Association (PCMA) Vice President of Policy Claire Wulf Winiarek has been selected as a member of the National Academy of Social Insurance (NASI), an organization dedicated to increasing public understanding of how social insurance contributes to
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on a new research paper, “Ending Pay for PBM Performance: Consequences for Prescription Drug Prices, Utilization, and Government Spending,” authored by University of Chicago Professor of
(Washington, D.C.) — In recognition of National Diabetes Month, the Pharmaceutical Care Management Association (PCMA) is outlining how pharmacy benefit managers, PBMs, are working to lower insulin costs and creating programs to support people with diabetes and improve health outcomes. “PBMs have been able
(Washington, D.C.) — Today, representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter brand and generic manufacturers; pharmacies and pharmacists across all practice settings, including health systems and hospitals, community, specialty, and managed care; supermarkets; wholesalers; pharmaceutical
Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaiser Health News analysis has
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on new National Health Expenditure (NHE) data from the Centers for Medicare & Medicaid Services: The latest NHE survey shows that the retail prescription drug net price index declined
See topline points from the “National Survey of Seniors Regarding the Medicare Part D Prescription Drug Benefit”
©2024 PCMA. All Rights Reserved.
